Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is ...

While Ozempic is rising in popularity, experts say the drug is not designed or approved for weight loss. (Oct. 3, 2024) ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

What if you would like to do some drinking on Ozempic? Digging into the answers with your healthcare team is essential. "We ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight ... of the total GLP-1 market, which ...

A triple-board-certified MD of lifestyle and obesity medicine lists the foods that will optimize your medication's efficacy ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Health officials in England are considering a staggered roll out of an obesity drug due to high levels of demand. Nearly a quarter of a million people are expected to receive the Mounjaro jab over the ...